DrugPatentWatch Database Preview
ZURAMPIC Drug Profile
When do Zurampic patents expire, and when can generic versions of Zurampic launch?
Zurampic is a drug marketed by Ironwood Pharms Inc and is included in one NDA. There are nine patents protecting this drug.
This drug has one hundred and ninety-three patent family members in forty countries.
The generic ingredient in ZURAMPIC is lesinurad. One supplier is listed for this compound. Additional details are available on the lesinurad profile page.
Summary for ZURAMPIC
| International Patents: | 193 |
| US Patents: | 9 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 61 |
| Patent Applications: | 64 |
| Drug Prices: | Drug price information for ZURAMPIC |
| DailyMed Link: | ZURAMPIC at DailyMed |
Generic Entry Opportunity Date for ZURAMPIC
Generic Entry Date for ZURAMPIC*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for ZURAMPIC
| Drug Class | Urate Transporter 1 Inhibitor |
| Mechanism of Action | Urate Transporter 1 Inhibitors Cytochrome P450 3A Inducers |
Synonyms for ZURAMPIC
| (5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid |
| {[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid |
| 09ERP08I3W |
| 2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid |
| 2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid |
| 2-(5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid |
| 2-[[5-Bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-acetic acid |
| 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid |
| 2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]thio]acetic acid |
| 2-{[5-broMo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid |
| 3777AH |
| 878672-00-5 |
| AC-29310 |
| Acetic acid, 2-((5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl)thio)- |
| Acetic acid,[[5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]- |
| ACN-050764 |
| AK323774 |
| AKOS027327368 |
| BCP06435 |
| BDBM37953 |
| C17H14BrN3O2S |
| CHEBI:90929 |
| CHEMBL2105720 |
| CS-1389 |
| D09921 |
| DB11560 |
| EX-A1289 |
| FGQFOYHRJSUHMR-UHFFFAOYSA-N |
| GTPL7673 |
| HY-15258 |
| KB-78121 |
| KS-00000LAE |
| LESINURAD |
| Lesinurad (RDEA-594) |
| Lesinurad (RDEA594 pound(c) |
| Lesinurad (RDEA594) |
| Lesinurad (USAN/INN) |
| Lesinurad [USAN:INN] |
| Lesinurad, >=98% (HPLC) |
| MolPort-039-138-666 |
| RDEA 594 |
| RDEA-594 |
| RDEA594 |
| s4640 |
| SB16705 |
| SC-94287 |
| SCHEMBL842962 |
| UNII-09ERP08I3W |
| US10093631, Compound Lesinurad |
| W-5949 |
| ZINC84757007 |
| Zurampic (TN) |
US Patents and Regulatory Information for ZURAMPIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ironwood Pharms Inc | ZURAMPIC | lesinurad | TABLET;ORAL | 207988-001 | Dec 22, 2015 | DISCN | Yes | No | See Pricing | See Pricing | See Pricing | ||||
| Ironwood Pharms Inc | ZURAMPIC | lesinurad | TABLET;ORAL | 207988-001 | Dec 22, 2015 | DISCN | Yes | No | See Pricing | See Pricing | See Pricing | ||||
| Ironwood Pharms Inc | ZURAMPIC | lesinurad | TABLET;ORAL | 207988-001 | Dec 22, 2015 | DISCN | Yes | No | See Pricing | See Pricing | Y | See Pricing | |||
| Ironwood Pharms Inc | ZURAMPIC | lesinurad | TABLET;ORAL | 207988-001 | Dec 22, 2015 | DISCN | Yes | No | See Pricing | See Pricing | Y | Y | See Pricing | ||
| Ironwood Pharms Inc | ZURAMPIC | lesinurad | TABLET;ORAL | 207988-001 | Dec 22, 2015 | DISCN | Yes | No | See Pricing | See Pricing | See Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ZURAMPIC
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2015172053 | See Pricing |
| Portugal | 2217577 | See Pricing |
| China | 103058944 | See Pricing |
| Singapore | 155246 | See Pricing |
| Australia | 2008329673 | See Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ZURAMPIC
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2135608 | 93169 | Luxembourg | See Pricing | PRODUCT NAME: LESINURAD , OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION DATE: 20160222 |
| 2217577 | CA 2019 00003 | Denmark | See Pricing | PRODUCT NAME: DUZALLO - ALLOPURINOL/LESINURAD OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SALTS THEREOF; REG. NO/DATE: EU/1/18/1300 20180827 |
| 2135608 | 288 5019-2016 | Slovakia | See Pricing | PRODUCT NAME: LESINURAD VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/15/1080 20160222 |
| 2217577 | 2019C/502 | Belgium | See Pricing | PRODUCT NAME: DUZALLO - ALLOPURINOL / LESINURAD OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE OU UN DE SES SELS; AUTHORISATION NUMBER AND DATE: EU/1/18/1300 20180827 |
| 2135608 | C02135608/01 | Switzerland | See Pricing | PRODUCT NAME: LESINURAD; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65925 07.04.2017 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
